# 🫘 Chronic Kidney Disease (CKD)

## 🔄 Understanding the AKI-CKD Continuum

![AKI to CKD Continuum showing progression from acute injury through acute kidney disease to chronic kidney disease](https://urinenephrology.org/2025_UDPA_Lectures_Live/assets/AKI_CKD.png)

CKD represents the endpoint of progressive kidney damage, but the relationship with acute injury is bidirectional - CKD increases AKI risk, and AKI accelerates CKD progression.

## 📋 CKD Definition (KDIGO 2024)

**Abnormalities of kidney structure or function present for \>3 months, with implications for health**

### 📊 Functional Criteria

- eGFR \<60 mL/min/1.73m² for \>3 months
- Albuminuria ≥30 mg/g (≥3 mg/mmol)
- Electrolyte abnormalities due to tubular disorders

### 🔬 Structural Criteria

- Pathologic abnormalities on biopsy
- Imaging abnormalities (polycystic, scarring)
- History of kidney transplantation

## 🎯 CKD Risk Stratification Matrix

The KDIGO risk matrix combines GFR and albuminuria to predict progression and guide monitoring frequency:

[TABLE]

## Comprehensive CKD Management

### 🩸 Anemia Management

Evidence-based approach to CKD anemia (final KDIGO 2026 guidance)

- **Iron Deficiency:** Absolute vs functional distinction
- **Hepcidin Axis:** Inflammation can reduce oral iron response
- **Iron route:** IV preferred in HD; individualize oral versus IV in nondialysis CKD/PD
- **ESA Therapy:** Goal is reducing transfusions
- **ESA maintenance:** Adult Hb goal below 11.5 g/dL; individualize risk

### 🦴 Mineral Bone Disorder

CKD-MBD management with 2024 evidence updates

- **Vitamin D Pathway:** 3-step synthesis disruption
- **PTH Management:** Serial trends; dialysis status changes interpretation
- **Evidence Update:** PRIMO/OPERA trial impacts
- **Before dialysis:** No established optimal PTH target; assess severity and progression
- **Avoid:** Routine vitamin D analogs (2017 KDIGO)

### ⚖️ Metabolic Acidosis

2024 KDIGO threshold update and treatment strategies

- **Clinical concern:** Consider treatment to prevent consequential acidosis, for example bicarbonate \<18 mmol/L
- **Evidence Base:** UBI study, protein catabolism
- **Treatment Options:** Sodium bicarbonate vs fruits/vegetables
- **Evidence:** Do not promise a fixed eGFR benefit from alkali
- **Monitor:** Trends, not single values

### 💊 Five Pillars Management

[📘 Comprehensive CKD Management 2025 Evidence Review](https://urinenephrology.org/2025_UDPA_Lectures_Live/ckd/comprehensive-ckd-management.html)

Comprehensive approach to slow CKD progression

- **Blood Pressure:** Target \<130/80 mmHg
- **RAAS Inhibition:** ACE-I/ARB first-line
- **SGLT2 Inhibitors:** Renoprotective effects
- **Protein Restriction:** 2024 evidence challenges
- **Diabetes Control:** A1C \<7% in most patients

### 🫀 Cardiorenal Disease

CV risk assessment and prevention in CKD

- **CV Risk:** 2-10× higher than general population
- **Risk Factors:** Traditional + CKD-specific
- **Prevention:** Statins, aspirin, lifestyle
- **Monitoring:** Coronary calcium scoring
- **Management:** Aggressive risk factor modification

### 🧮 Interactive Calculators

Clinical decision support tools

- **CKD Management:** Comprehensive assessment
- **Anemia Workup:** Iron status evaluation
- **PTH Management:** Stage-specific recommendations
- **Acidosis Treatment:** Threshold-based guidance
- **Evidence-Based:** Latest guideline integration

### 💊 Renal Pharmacology & Medication Safety

Evidence-based medication management in CKD

- **Dose Adjustments:** GFR-based dosing strategies
- **Nephrotoxin Avoidance:** High-risk medications in CKD
- **Drug Interactions:** Critical pharmacokinetic considerations
- **Dialysis Dosing:** Supplemental dosing for dialyzed drugs
- **Medication Safety:** Comprehensive prescribing guidance

✅ Comprehensive Guide

## 🚨 CKD Emergency Recognition

### Severe Anemia (Hgb \<7-8 g/dL)

- Consider urgent transfusion if symptomatic
- Evaluate for bleeding, hemolysis
- Check iron studies, B12, folate

### Severe Hyperkalemia (K+ \>6.5)

- ECG changes with acidosis
- Calcium gluconate, insulin/dextrose
- Consider emergent dialysis

### Severe Acidosis (HCO₃ \<12)

- Assess for intercurrent illness
- Consider IV bicarbonate if pH \<7.1
- Monitor for respiratory compensation

### Uremic Emergency

- Altered mental status, pericarditis
- Bleeding diathesis, uremic frost
- Consider emergent hemodialysis

## 📊 CKD Management Calculator

This educational calculator prompts review; it does not prescribe treatment. Choose HD versus PD explicitly. For anemia, HD iron-entry criteria are ferritin ≤500 ng/mL and TSAT ≤30%; nondialysis/PD criteria are ferritin \<100 with TSAT \<40%, or ferritin 100–\<300 with TSAT \<25%. Withhold routine iron at ferritin \>700 or TSAT ≥40%. PTH interpretation requires the laboratory assay limit and serial calcium/phosphate results: approximately 2–9× the assay limit applies to dialysis, while optimal PTH before dialysis is unknown. A PTH \>300 alone does not trigger calcitriol. Consider acidosis treatment based on clinical consequences (for example bicarbonate \<18 mmol/L), with BP, potassium, and volume monitoring.

### Patient Parameters

Hemoglobin (g/dL): Ferritin (ng/mL): TSAT (%): Bicarbonate (mEq/L): CKD Stage: PTH (pg/mL): PTH assay upper normal limit (pg/mL):

### Management Recommendations

Enter patient parameters to see recommendations

## 💎 Key Clinical Pearls

### 🩸 Anemia Management

- Choose oral or IV iron in nondialysis CKD/PD by severity, tolerance, response, access, and preference; IV iron is preferred in HD
- ESA goal is reducing transfusions, not normalizing Hgb
- Check iron studies before starting ESA therapy

### 🦴 PTH Management

- Address modifiable factors before starting vitamin D analogs
- Modest PTH elevation can be adaptive; assess serial values with calcium, phosphate, intake, and vitamin D
- Do not routinely use active vitamin D in G3a–G5 without dialysis; reserve it for severe, progressive hyperparathyroidism in G4–G5 after modifiable causes are addressed

### ⚖️ Acidosis Management

- KDIGO 2024 gives bicarbonate \<18 mmol/L as an example warranting treatment consideration, not an automatic universal threshold
- Select dietary or pharmacologic therapy with potassium, nutrition, BP, and fluid status in mind; outcome equivalence is not established
- Monitor trends, not single values

### 🎯 Essential CKD Learning Points

#### 📊 Risk Stratification

- KDIGO matrix combines GFR + albuminuria
- Highest risk within KDIGO A3: nephrotic-range proteinuria \>3 g/g (formal KDIGO uses A1–A3; the \>3000 mg/g tier shown in the heat map above is a teaching emphasis, not a separate KDIGO category)
- Monitor frequency based on risk level
- Early nephrology referral for high risk

#### 🎯 Evidence-Based Management

- 2024 guidelines emphasize individualization
- Avoid routine vitamin D analogs
- Consider consequential acidosis (for example bicarbonate \<18 mmol/L), with individualized treatment
- IV iron preferred in HD; oral versus IV individualized before dialysis and in PD

#### 🚨 Emergency Recognition

- Severe anemia may require transfusion
- Hyperkalemia with ECG changes
- Uremic emergencies need dialysis
- Severe acidosis evaluation

#### 💡 Clinical Integration

- AKI-CKD continuum concept
- Cardiorenal disease prevention
- Five pillars approach
- Regular monitoring and adjustment

[KDIGO 2017 CKD-MBD recommendations 4.2.1–4.2.4](https://pmc.ncbi.nlm.nih.gov/articles/PMC6340919/) · [Final KDIGO 2026 anemia guideline](https://kdigo.org/wp-content/uploads/2026/01/KDIGO-2026-Anemia-in-CKD-Guideline.pdf)

## 📚 Sources

1.  **Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group.** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int.* 2024;105(4S):S117-S314. [PMID: 38490803](https://pubmed.ncbi.nlm.nih.gov/38490803/). *— Foundational KDIGO 2024 CKD guideline; G/A staging matrix uses A1/A2/A3 only — there is no A4 tier.*
2.  **Heerspink HJL, Stefansson BV, Correa-Rotter R, et al; DAPA-CKD Trial Committees.** Dapagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med.* 2020;383(15):1436-1446. [PMID: 32970396](https://pubmed.ncbi.nlm.nih.gov/32970396/). *— DAPA-CKD primary composite HR 0.61.*
3.  **EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, et al.** Empagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med.* 2023;388(2):117-127. [PMID: 36331190](https://pubmed.ncbi.nlm.nih.gov/36331190/). *— Empagliflozin across full eGFR 20-90 spectrum and albuminuria range; HR 0.72 primary composite.*
4.  **Bakris GL, Agarwal R, Anker SD, et al; FIDELIO-DKD Trial.** Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. *N Engl J Med.* 2020;383(23):2219-2229. [PMID: 33264825](https://pubmed.ncbi.nlm.nih.gov/33264825/). *— Finerenone CKD outcome benefit in T2D.*
5.  **Perkovic V, Tuttle KR, Rossing P, et al; FLOW Trial.** Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. *N Engl J Med.* 2024;391(2):109-121. [PMID: 38785209](https://pubmed.ncbi.nlm.nih.gov/38785209/). *— FLOW trial; GLP-1RA semaglutide kidney outcomes in T2D-CKD; HR 0.76 composite kidney+CV.*
6.  **Perkovic V, Jardine MJ, Neal B, et al; CREDENCE Trial.** Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. *N Engl J Med.* 2019;380(24):2295-2306. [PMID: 30990260](https://pubmed.ncbi.nlm.nih.gov/30990260/). *— Foundational SGLT2i renal-outcomes trial in T2D nephropathy.*
7.  **de Zeeuw D, Remuzzi G, Parving HH, et al.** Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. *Circulation.* 2004;110(8):921-927. [PMID: 15302780](https://pubmed.ncbi.nlm.nih.gov/15302780/). *— Foundational evidence that albuminuria is itself a CV risk factor and therapeutic target.*

📚 For Educational Purposes Only

© 2025 Andrew Bland MD - All Rights Reserved


---

[Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/ckd/index.html) · Markdown synchronized October 3, 2026.